BEIJING, Aug. 27, 2014 /PRNewswire/ -- Sinovac Biotech
Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products
in China, today announced the
results of the Company's 2014 Annual General Meeting of
Shareholders held on Wednesday, August 27,
2014 in Beijing, PRC. The
required quorum, a majority of the common shares outstanding, was
voted by proxy.
The Company's shareholders approved the following
proposals:
- The re-election of Weidong Yin,
Yuk Lam Lo, Simon Anderson, Kenneth
Lee and Meng Mei as the
Company's directors until the next annual meeting of shareholders
and or until their successors are duly elected;
- The audited consolidated financial statements of the Company
for the financial year ended December 31,
2013 together with the Report of Independent Registered
Public Accounting Firm thereon and the notes thereto;
- The appointment of Ernst &Young Hua Ming LLP as the
independent auditor of the Company for the fiscal year ending
December 31, 2014 and to authorize
the directors of the Company to fix such independent auditor's
remuneration.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacturing, and
commercialization of vaccines that protect against human infectious
diseases. Sinovac's product portfolio includes vaccines against
hepatitis A and B, seasonal influenza, H5N1 pandemic influenza
(avian flu), H1N1 influenza (swine flu), mumps and canine rabies.
In 2009, Sinovac was the first company worldwide to receive
approval for its H1N1 influenza vaccine, which it has supplied to
the Chinese Government's vaccination campaign and stockpiling
program. The Company is also the only supplier of the H5N1 pandemic
influenza vaccine to the government stockpiling program. Sinovac
has filed a new drug application with the China Food & Drug
Administration for its proprietary enterovirus 71 vaccine, having
been proven effective in preventing hand, foot and mouth disease in
infants and children during its Phase III trial. The company is
currently developing a number of new products including a
Sabin-strain inactivated polio vaccine, pneumococcal
polysaccharides vaccine, pneumococcal conjugate vaccine and
varicella vaccine. Sinovac primarily sells its vaccines in
China, while also exploring growth
opportunities in international markets. The Company has exported
select vaccines to Mongolia,
Nepal, the Philippines and Mexico, and was recently granted a license to
commercialize its hepatitis A vaccine in Chile. For more information, please visit the
Company's website at www.Sinovac.com .
Contact
Sinovac Biotech Ltd.
Helen Yang / Chris Lee
Tel: +86-10-8279-9659 / 9696
Fax: +86-10-6296-6910
Email: ir@sinovac.com
ICR Inc.
Bill Zima
U.S: 1-646-308-1707
Email: william.zima@icrinc.com
SOURCE Sinovac Biotech Ltd.